The EPO’s plausibility approach and the industrial application requirement in biotech patenting

This presentation will discuss the most recent developments relating to the “industrial application” requirement with a special emphasis on gene and protein-related inventions in Europe. In addition to providing a brief overview of the applicable legislative framework, this presentation will address relevant EPO practice and the UK Supreme Court’s seminal decision in HGS v Eli Lilly.


A presentation given at a 5 days intensive training for practitioners/professionals in Pharma Law & Policy (CSU), 13 – 17 August 2012, 9, at the University of Copenhagen, Frederiksberg Campus